Gibson Christopher 的 Form 4 申報
Recursion Pharmaceuticals, Inc.（RXRX），2023/2/3 申報
- 申報編號
- 0001209191-23-007041
- 申報時間
- 2023/2/3
- 交易日
- 2023/2/1-2/2
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 11 筆非衍生性交易、5 筆衍生性交易。公開市場賣出合計 $19.4 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Gibson ChristopherCIK 0001856369 | 董事、高階主管（執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2023/2/1 | Class A Common Stock | A公司授予取得 | +406,800 | $0.00 | $0 | 932,605 | 直接 | |
| 2023/2/1 | Class A Common Stock | A公司授予取得 | +11,050 | $0.00 | $0 | 943,655 | 直接 | |
| 2023/2/1 | Class A Common Stock | F扣股繳稅處分 | −1,382 | $8.55 | −$11,816.1 | 942,273 | 直接 | |
| 2023/2/2 | Class A Common Stock | C轉換取得 | +18,500 | $0.00 | $0 | 960,773 | 直接 | |
| 2023/2/2 | Class A Common Stock | S賣出處分 | −18,500 | $9.22F6 | −$170,570 | 942,273 | 直接 | |
| 2023/2/2 | Class A Common Stock | C轉換取得 | +500 | $0.00 | $0 | 500 | 間接 | |
| 2023/2/2 | Class A Common Stock | S賣出處分 | −500 | $9.21F8 | −$4,605 | 0 | 間接 | |
| 2023/2/2 | Class A Common Stock | C轉換取得 | +1,000 | $0.00 | $0 | 1,000 | 間接 | |
| 2023/2/2 | Class A Common Stock | S賣出處分 | −1,000 | $9.21F10 | −$9,210 | 0 | 間接 | |
| 2023/2/2 | Class A Common Stock | C轉換取得 | +1,000 | $0.00 | $0 | 1,000 | 間接 | |
| 2023/2/2 | Class A Common Stock | S賣出處分 | −1,000 | $9.20F12 | −$9,200 | 0 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2023/2/1 | Class A Common Stock | A公司授予取得 | +813,600 | $0.00 | $0 | 813,600 | 直接 | |
| 2023/2/2 | Class A Common Stock | C轉換處分 | −18,500 | $0.00 | $0 | 6,640,334 | 直接 | |
| 2023/2/2 | Class A Common Stock | C轉換處分 | −500 | $0.00 | $0 | 539,500 | 間接 | |
| 2023/2/2 | Class A Common Stock | C轉換處分 | −1,000 | $0.00 | $0 | 529,000 | 間接 | |
| 2023/2/2 | Class A Common Stock | C轉換處分 | −1,000 | $0.00 | $0 | 125,875 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F6
This transaction was executed in multiple trades at prices ranging from $8.63 to $9.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
表 I 有 1 筆交易的價格引用這則附註。
- F8
This transaction was executed in multiple trades at prices ranging from $8.63 to $9.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
表 I 有 1 筆交易的價格引用這則附註。
- F10
This transaction was executed in multiple trades at prices ranging from $8.66 to $9.52 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
表 I 有 1 筆交易的價格引用這則附註。
- F12
This transaction was executed in multiple trades at prices ranging from $8.64 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
表 I 有 1 筆交易的價格引用這則附註。